| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma |
NCT05635487: A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients |
|
|
| Recruiting | 2 | 61 | RoW | SHR-A1811, Pyrotinib | Shengjing Hospital, Jiangsu HengRui Medicine Co., Ltd. | HER2-positive Breast Cancer | 02/24 | 02/29 | | |
NCT06340230: SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer |
|
|
| Not yet recruiting | 2 | 93 | RoW | SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection | Shengjing Hospital, Jiangsu HengRui Medicine Co., Ltd. | ER Positive/HER2 Low Breast Cancer | 02/26 | 02/31 | | |
NCT06361979: SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases |
|
|
| Not yet recruiting | 2 | 30 | NA | SHR-A1811, Bevacizumab | Huihua Xiong | Breasr Cancer | 05/25 | 05/26 | | |
NCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 65 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | 09/25 | 09/25 | | |
NCT06411457: SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 20 | RoW | SHR-A1811+Adebrelimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 05/25 | 05/26 | | |
NCT05911958: A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer |
|
|
| Recruiting | 2 | 66 | RoW | SHR-A1811 for injection, SHR-A1811 group | Henan Cancer Hospital | HER2 Low Breast Carcinoma | 05/24 | 05/29 | | |
NCT06433609: Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer |
|
|
| Not yet recruiting | 2 | 131 | RoW | SHR-A1811, SHR-A1921, Adebrelimab | Beijing GoBroad Hospital | Advanced Breast Cancer | 07/27 | 11/27 | | |
NCT05349409: A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers |
|
|
| Enrolling by invitation | 2 | 212 | RoW | SHR-A1811, Fluzoparib Capsule, SHR-3162 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 11/24 | 05/25 | | |
NCT05924256: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing |
|
|
| Recruiting | 2 | 88 | RoW | SHR-A1811, SHR 3680 + leuprolide, SHR-A1921 | Fudan University | Advanced Salivary Gland Carcinoma | 09/25 | 09/26 | | |
NCT05769010: Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases |
|
|
| Recruiting | 2 | 100 | RoW | SHR-A1811, Pyrotinib, Bevacizumab | Henan Cancer Hospital | Metastatic Breast Cancer | 10/25 | 04/26 | | |
| Recruiting | 2 | 140 | RoW | PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, TROP2 ADC, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, RTK Inhibitor | Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University | Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer | 12/25 | 12/26 | | |
NCT05749588: FUSCC Refractory TNBC Platform Study (FUTURE2.0) |
|
|
| Recruiting | 2 | 120 | RoW | A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, SHR-1210, B1: TROP2 ADC, B2: TROP2 ADC with Camrelizumab, C1: SHR-A1811, C2: SHR-A1811 with BP102, D1: TROP2 ADC, D2: TROP2 ADC with BP102, E1: SHR-A1811, F1: TROP2 ADC, G1: SHR-A1811, H1: TROP2 ADC | Fudan University | Triple-negative Breast Cancer | | | | |
NCT05353361: A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer |
|
|
| Recruiting | 2 | 402 | RoW | SHR-A1811：Pyrotinib, SHR-A1811；Pertuzumab, SHR-A1811；Adebrelimab, SHR-A1811；Albumin paclitaxel | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 12/25 | 12/25 | | |
NCT05896020: A Study of SHR-A1811 in Subjects With Gynaecologic Oncology |
|
|
| Recruiting | 2 | 225 | RoW | SHR- A1811 | Jiangsu HengRui Medicine Co., Ltd. | Gynaecological Malignancies | 06/26 | 06/26 | | |
NCT05671822: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer |
|
|
| Recruiting | 2 | 156 | RoW | SHR-A1811；SHR-1701；capecitabine；oxaliplatin | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | 07/26 | 07/26 | | |
NCT04818333: A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 157 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/25 | 06/25 | | |
NCT05482568: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 324 | RoW | SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Non-small Cell Lung Cancer | 11/23 | 12/24 | | |
NCT06222879: Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer |
|
|
| Not yet recruiting | 1/2 | 350 | NA | HRS-8080; SHR-A1811, HRS-8080; SHR-A2009, SHR-A2009; SHR-1316 | Shandong Suncadia Medicine Co., Ltd. | Breast Cancer | 10/26 | 10/26 | | |
NCT05792410: A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer. |
|
|
| Not yet recruiting | 1/2 | 300 | NA | SHR-A1811 & Dalpiciclib Isethionate Tablets, SHR-A1811 & Fulvestrant, SHR-A1811 & Bevacizumab injection | Jiangsu HengRui Medicine Co., Ltd. | HER2 Low Advanced or Metastatic Breast Cancer | 02/24 | 02/25 | | |
FASCINATE-N, NCT05582499: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy |
|
|
| Recruiting | 1/2 | 716 | RoW | Dalpiciclib, SHR-6390, Pyrotinib, SHR-A1811, SHR-1316, Camrelizumab, SHR-1210, Trophoblast cell-surface antigen 2 (TROP2) ADC, Pertuzumab, Trastuzumab, Goserelin, Letrozole, Nab paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide, Fluzoparib, SHR-3162, HER2 ADC | Fudan University | Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer | 09/24 | 09/25 | | |
NCT05845138: A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. |
|
|
| Recruiting | 1/2 | 116 | RoW | SHR-A1811 for injection ; capecitabine | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Breast Cancer | 12/24 | 12/25 | | |
GALAXY, NCT05824325: Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（） |
|
|
| Active, not recruiting | 1/2 | 56 | RoW | SHR-A1811, TROP2 ADC | Fudan University | Breast Cancer | 04/25 | 10/26 | | |
NCT06015048: A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
